Name: Nesfatin-1
Brand: Research-Grade
Availability: InStock

Question 1

How does nesfatin-1 differ from GLP-1 receptor agonists for appetite suppression?

Accepted Answer

Nesfatin-1 and GLP-1 receptor agonists (semaglutide, liraglutide) both suppress appetite, but through largely different mechanisms and at very different stages of development. GLP-1 agonists work primarily through peripheral GLP-1 receptors and brainstem satiety centers, have extensive human clinical data, and are FDA-approved for obesity and diabetes. Nesfatin-1 acts through central melanocortin pathways and its specific receptor has not yet been definitively identified. It has no human therapeutic trial data. They represent fundamentally different pharmacological approaches to appetite regulation.

Question 2

Does nesfatin-1 cross the blood-brain barrier?

Accepted Answer

Yes, and this is one of its most pharmacologically significant properties. Nesfatin-1 crosses the blood-brain barrier bidirectionally via a non-saturable mechanism, likely involving transmembrane diffusion. This means peripherally administered nesfatin-1 can access hypothalamic appetite centers directly — unusual for a peptide of its size (82 amino acids). This BBB permeability has been demonstrated using radioiodinated nesfatin-1 tracing studies and is consistent with the observation that both central (intracerebroventricular) and peripheral (intraperitoneal) administration produce appetite-suppressing effects.

Question 3

What is the nesfatin-1 receptor?

Accepted Answer

Remarkably, despite nearly two decades of research since nesfatin-1's discovery, its specific receptor has not been definitively identified. This is an unusual situation in peptide pharmacology. Functional studies clearly demonstrate that nesfatin-1 activates specific signaling cascades — its effects are dose-dependent, saturable at the cellular level, and require melanocortin receptor signaling downstream. Several candidate receptors have been proposed, and binding studies suggest a membrane-associated target, but the molecular identity of the primary nesfatin-1 receptor remains one of the field's open questions.

Question 4

Are circulating nesfatin-1 levels altered in obesity?

Accepted Answer

Yes. Multiple cross-sectional studies have found that circulating nesfatin-1 levels are reduced in obese individuals compared to normal-weight controls, and are inversely correlated with BMI, waist circumference, and insulin resistance. Nesfatin-1 levels are also lower in type 2 diabetes. Interestingly, bariatric surgery has been shown to increase circulating nesfatin-1 levels, coinciding with metabolic improvements. However, it remains unclear whether reduced nesfatin-1 is a cause or consequence of obesity — the associational nature of this data limits causal interpretation.

Question 5

Does nesfatin-1 affect glucose metabolism independently of appetite?

Accepted Answer

Yes. Beyond its central appetite-suppressing effects, nesfatin-1 has direct metabolic actions in peripheral tissues. In pancreatic beta cells, nesfatin-1 potentiates glucose-stimulated insulin secretion through increased intracellular calcium signaling. In hepatocytes, it modulates gluconeogenesis. In adipocytes, it enhances glucose uptake. These peripheral effects are independent of its central anorexigenic action and suggest that nesfatin-1 has a direct role in glucose homeostasis — making it a potential dual-action target for both obesity and type 2 diabetes.

Question 6

What are the known side effects of nesfatin-1?

Accepted Answer

Human safety data for exogenous nesfatin-1 administration does not exist. In rodent studies, centrally administered nesfatin-1 has been associated with increased anxiety-like behavior and activation of stress pathways (CRH, HPA axis activation at high doses), which is consistent with the overlap between appetite-regulating and stress-response circuits. The anorexigenic effect itself — reduced food intake — could be considered an adverse effect if excessive. The complete side-effect profile in humans is unknown and cannot be extrapolated from animal data.

Question 7

Could nesfatin-1 be developed as an anti-obesity drug?

Accepted Answer

The theoretical potential exists, but significant obstacles remain. Key challenges include: (1) the receptor has not been identified, making rational drug design difficult; (2) the peptide's relatively short half-life requires formulation optimization; (3) the relationship between nesfatin-1 and stress/anxiety pathways raises safety concerns for chronic use; (4) the competitive landscape is dominated by GLP-1 agonists with extensive clinical data and established efficacy; and (5) no pharmaceutical company has initiated clinical trials with nesfatin-1. The academic interest is strong, but the commercial development pathway is unclear.

Question 8

Does nesfatin-1 affect sleep?

Accepted Answer

Preclinical evidence suggests nesfatin-1 has sleep-modulatory effects, though the direction of influence appears context-dependent. Central administration of nesfatin-1 has been shown to suppress REM sleep and increase wakefulness in some rodent studies, while peripheral administration may have different effects. Nesfatin-1 is expressed in sleep-regulatory brain regions and its levels show circadian variation. The clinical significance of these sleep effects is unknown, but they represent another dimension of nesfatin-1's biology that extends beyond simple appetite regulation.

Question 9

How is nesfatin-1 related to nucleobindin-2?

Accepted Answer

Nesfatin-1 is produced by enzymatic cleavage of nucleobindin-2 (NUCB2), a 396-amino-acid protein with diverse cellular functions including calcium binding, DNA binding, and Golgi trafficking. NUCB2 is cleaved by the prohormone convertase PC1/3 to produce three fragments: nesfatin-1 (residues 1-82), nesfatin-2 (residues 85-163), and nesfatin-3 (residues 166-396). Of these three fragments, only nesfatin-1 has demonstrated biological activity in appetite and metabolic regulation — the other fragments appear to be biologically inert in tested assays.

Question 10

Is exogenous nesfatin-1 available for research?

Accepted Answer

Recombinant and synthetic nesfatin-1 is available from several research biochemical suppliers, though it is expensive due to the peptide's length (82 amino acids) and the technical demands of synthesis or recombinant production. It is sold strictly for in-vitro and animal research purposes. The commercially available forms vary in source (recombinant E. coli expression vs. chemical synthesis), purity, and species specificity (human vs. rat sequence). No preparation is approved for human use, and the research-grade material is not manufactured to pharmaceutical standards.

Origin / Manufacturer	Endogenous
Active Components	Nesfatin-1 peptide (recombinant or synthetic)Bacteriostatic water (for reconstitution)
Storage	Lyophilized: -20°C recommended. Reconstituted: 2–8°C
Shelf Life	Lyophilized 12–24 months at -20°C; reconstituted 14 days refrigerated
Form Factor	Lyophilized powder (0.5–1 mg vial, research grade)

Nesfatin-1

Specifications

Frequently Asked Questions

Related Peptides

Cagrilintide

Liraglutide

Semaglutide

Tirzepatide